Ascletis Pharmaceuticals

weight loss scale weigh measure tape obesity overweight
Biotech

Ascletis eyes quarterly GLP-1 dosing following phase 2 readout

Ascletis posted phase 2 data on its ultra-long-acting GLP-1, generating early evidence that the formulation may support quarterly maintenance dosing.
Nick Paul Taylor Mar 10, 2026 8:20am
obesity overweight weight loss weigh

Ascletis reports 7.7% weight loss for oral GLP-1 contender

Dec 8, 2025 8:35am
Acne

Ascletis prepares for China regulators after acne pill ph. 3 win

Jun 4, 2025 5:08am
reshuffle pipeline target reorganize shift change

Ascletis pulls FXR agonist from pipeline over phase 2 data

Apr 3, 2024 8:50am